期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

系统性硬化的诊断和治疗 被引量：1

Diagnosis and treatment of systemic sclerosis
下载PDF
导出
摘要 系统性硬化是一种慢性结缔组织疾病,它不仅侵犯皮肤、关节肌肉,还侵犯包括肺、肾、心脏、胃肠道等在内的内脏器官。本文主要介绍了系统性硬化的分类;目前应用的诊断标准及其局限性;国际上开展的VEDOSS试验的内容及意义;目前常用的药物治疗以及一些有希望的新治疗方法。 Systemic sclerosis is a chronic connective tissue disease which not only affects the skin,joint and muscle,but also invades the lung,kidney,heart,gastrointestinal tract and other organs.Here we will introduce the classification of systemic sclerosis,the current diagnostic criteria and its limitations,the international VEDOSS clinical trial and the common therapy plus some promising new treatments.
作者 侯勇 曾小峰
机构地区 中国医学科学院中国协和医科大学北京协和医院免疫内科
出处 《实用医院临床杂志》 2011年第2期2-4,共3页 Practical Journal of Clinical Medicine
关键词 系统性硬化 诊断 治疗 Systemic sclerosis Diagnosis Treatement
分类号 R593.2 [医药卫生—内科学]
  • 相关文献

参考文献13

  • 1Hofstee HM, Vonk Noordegraaf A, Voskuyl AE, et al. Nailfold capil- lary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis [ J]. Ann Rheum Dis, 2009,68(2) :191-195.
  • 2Matucci-Cerinic M, Allanore Y, Czirjàk L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Re- search group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy [ J ]. Ann Rheum Dis,2009,68 (9) :1377-1380.
  • 3Kowal-Bielecka O, Landew6 R, Avouac J, et al. EULAR recommen- dations for the treatment of systemic sclerosis : a report from the EU- LAR Scleroderma Trials and Research group (EUSTAR) [ J]. Ann Rheum Dis,2009,68(5 ) :620-628.
  • 4Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclero- sis. A multicenter, placebo-controlled, double-blind study[ J]. Ann Intern Med, 1994,120 : 199-206.
  • 5Korn JH, Mayes M, Matucci Cerinic M, et al, for the RAP1DS-1 Study Group. Digital Ulcers in Systemic Sclerosis. Prevention by Treatment With Bosentan, an Oral Endothelin Receptor Antagonist [ J ]. Arthri- tis Rheum ,2004,50:3985-3993.
  • 6Steen V. D. , Constantino J. P. , Shapiro A. P. , et al : Outcome of renal crisis in systemic sclerosis : Relation to the availability of converting enzyme inhibitors (ACE) [ J ]. Ann Intern Med, 1990,113 : 352- 357.
  • 7Scorza R, Rivolta R, Mascagni B, et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis [ J]. J Rheumatol, 1997,24 : 1944-1948.
  • 8Hunzelmann N, Krieg T. Scleroderma. from pathophysiology to novel therapeutic approaches [ J ]. Exp Dermatol, 2010,19 ( 5 ) : 393-400.
  • 9Resenbloom J, Castro SV, Jimenez SA. Narrative review:fibrotic dis- eases:cellular and molecular mechanisms and novel therapies [ J]. Ann Intern Med,2010,152(3) :159-166.
  • 10Distler JH, Disfler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis:towards molecular targe- ted therapies[J]. Ann Rheum Dis,2010,69:48-51.

二级参考文献8

  • 1Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol, 1995, 22: 1217-1219.
  • 2Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum, 1980, 23: 137-145.
  • 3Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hcmatopoiesis-supportive function and other potentials. Haematologica, 2006, 91: 1017-1026.
  • 4Sun LY, Zhang HY, Feng XB, et al. Abnormality of bone marrow-derived stem cell in patient with systemic lupus erythematosus. Lupus, 2007, 16: 121-128.
  • 5Lakos G, Takagawa S, Chen S J, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol, 2004, 165: 203-217.
  • 6Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res, 2004, 296: 89-93.
  • 7Ono S, Imai T, Shimizu N. Decreased plasma levels of fibronectin in amyotrophie lateral sclerosis. Acta Neurol Scand, 2000, 101: 391-394.
  • 8Fatini C, Guiducci S, Abbate R, et al. Vascular injury in systemic sclerosis:angiotensin-converting enzyme insertion/deletion poiymorphism. Curt Rheumatol Rep, 2004, 6: 149-155.

共引文献7

同被引文献5

  • 1Poormoghim H,Lucas M,Fertig N,et al.Systemic sclerosis sine scleroderma:demographic,clinical,and serologic features and survival in forty-eight patients[ J ]. Arthritis Rheum,2000,43 ( 2 ) :444-451.
  • 2Slobodin G,Rosner I,Rozenbaum M,et al.Systemic sclerosis sine scleroderma:is it always the same disease? Report of three patients and discussion[J]. Rheumatology International,2002,22 ( 4 ) :170-172.
  • 3Lomeo RM,Cornella RJ,Schabel SI,et al.Progressive systemic sclerosis sine sclero pulmonary interstitial fibrosis derma presenting as [ J ].The American Journal of Medicine,1989,87 ( 5 ) :525-527.
  • 4徐东,李梦涛,赵久良,侯勇,王迁,赵岩,张奉春,曾小峰.系统性硬化症的诊治现状[J].中华临床免疫和变态反应杂志,2012,6(1):38-42. 被引量：10
  • 5郑汉朋,项剑瑜,刘绪明,邱乾德.11例获得型肢端骨质溶解症X线表现[J].放射学实践,2012,27(5):545-548. 被引量：1

引证文献1

实用医院临床杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部